[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620249":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":31,"centralContacts":32,"locations":31,"responsibleParty":38,"collaborators":31,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":31,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":31,"enrollmentInfo":51,"targetDuration":31,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":64,"whyStopped":31,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":31},{"fullName":5,"class":6},"University of California, Los Angeles","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Suzetrigine Arm","EXPERIMENTAL","Patients in both groups will receive a common multimodal pain control regimen which includes a preoperative regional anesthesia, a 14-day supply of 1000mg acetaminophen BID, and a 14-day supply of 500mg naproxen BID. Patients randomized to the Suzetrigine arm will receive a loading dose of Suzetrigine 100mg in PACU postoperatively and a 7-day supply of 50mg suzetrigine BID for 1 week total.\n\nPatients in this group will also receive 25 tablets of 5mg of oxycodone for rescue pain control.",[13],"Drug: Suzetrigine",{"label":15,"type":10,"description":16,"interventionNames":17},"Opioid Arm","Patients in both groups will receive a common multimodal pain control regimen which includes a preoperative regional anesthesia, a 14-day supply of 1000mg acetaminophen BID, and a 14-day supply of 500mg naproxen BID. Patients randomized to the Opioid arm will also receive 25 tablets of 5mg of oxycodone and will not receive a Suzetrigine prescription.",[18],"Drug: Multimodal Pain Regimen",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Suzetrigine","Patients in this group will receive a preoperative regional anesthesia block, a 14-day supply of 1000mg acetaminophen BID, a 14-day supply of 500mg naproxen BID, a loading dose of Suzetrigine 100mg in PACU postoperatively, a 7-day supply of 50mg suzetrigine BID and 25 tablets of 5mg of oxycodone for rescue pain control postoperatively.",[9],[26],"Journavx",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Multimodal Pain Regimen","Patients in this group will receive a preoperative regional anesthesia block, a 14-day supply of 1000mg acetaminophen BID, a 14-day supply of 500mg naproxen BID, and 25 tablets of 5mg of oxycodone for PRN pain control postoperatively.",[15],null,[33],{"name":34,"role":35,"phone":36,"phoneExt":31,"email":37},"Jomar Aryee, MD","CONTACT","3108256557","jaryee@mednet.ucla.edu",{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"PRINCIPAL_INVESTIGATOR","Jomar Aryee","Orthopaedic Sports Fellow","100620249","phase-4-suzetrigine-versus-usual-care-opioids-for-postop-pain-in-sports-100620249",false,"NCT07355166","Suzetrigine Versus Usual-care Opioids for Postop Pain in Sports","Suzetrigine Versus Usual-care Opioids for Postoperative Pain After Common Ambulatory Orthopaedic Sports Procedures - A Randomized Control Trial","Inclusion Criteria:\n\n* Patients undergoing reconstruction of primary ACL tear\n\nExclusion Criteria:\n\n* Concurrent ligamentous injuries requiring surgical intervention\n* Full thickness cartilage injury requiring discrete surgical intervention\n* Chronic opioid use\n* Significant hepatic disease (Child\u002FPugh C)\n* Women who are pregnant or breastfeeding\n* Women of childbearing age using hormonal contraceptives containing progestins other than levonorgestrel and norethindrone\n* Allergies or intolerance to any study medications\n* Inability to complete ePROs (due to literacy or infirmity)","ALL","18 Years",{"count":52,"type":53},140,"ESTIMATED","INTERVENTIONAL",[56],"PHASE4","The goal of this clinical trial is to learn if a Suzetrigine-based multimodal pain regimen can reduce the volume of opioid consumption while maintaining non-inferior pain control compared to an opioid-based multimodal pain regimen after common ambulatory orthopaedic sports procedures. The main questions it aims to answer are:\n\n1. Does including Suzetrigine in the multimodal pain regimen lower the volume of opioids consumed by participants while maintaining non-inferior pain control?\n2. How does the side-effect profile of a Suzetrigine-based multimodal postop pain regimen compare to that of an opioid-based multimodal postoperative pain regimen?\n\nEligible participants will be assigned to receive one of the postop pain regimens and report their opioid use, their pain level, and the side effects they faced every day for 7 days.",[59],"Postoperative Pain Management",[22,26,61,62,63,59],"Opioid Use","ACL Reconstruction","Rotator Cuff Repair","NOT_YET_RECRUITING","2026-01-19",{"date":67,"type":68},"2026-01-21","ACTUAL",{"date":70,"type":53},"2026-02",{"date":72,"type":53},"2026-07",{"name":5,"class":6}]